Literature DB >> 3262323

Left ventricular function during propofol and fentanyl anesthesia in patients with coronary artery disease: assessment with a radionuclide approach.

J Y Lepage1, M L Pinaud, J H Hélias, C M Juge, A Y Cozian, R Farinotti, R J Souron.   

Abstract

Using gated radionuclide ventriculography and invasive cardiac monitoring, the effects of propofol alone and in combination with fentanyl on left ventricular (LV) volumes and function were investigated in 10 ASA III, unpremedicated patients (51-75 years) with coronary artery disease (NYHA II-III). Anesthesia was induced with propofol (2 mg/kg) followed by an infusion (100 micrograms.kg-1.min-1). Vecuronium (0.05 mg/kg) was administered and ventilation (FIO2, 1.0) was manually controlled via a face mask (FECO2, 4-5%). Data acquisitions were serially obtained over 15 minutes after the bolus IV injection of propofol and 5 minutes after the injection of fentanyl (5 micrograms/kg). Propofol induced a rapid decrease (15%) in mean arterial pressure (MAP) exclusively related to a decrease in cardiac index (CI), without reduction in indexed systemic vascular resistances (SVRI). Despite the decrease in MAP, heart rate did not change. The decrease in CI was associated with a lower preload. After the addition of fentanyl, MAP decreased significantly (35%) below the last set of propofol measurements. The decrease in MAP was associated with a reduction in CI and SVRI. Fentanyl was also associated with a significant decrease in heart rate (16%) resulting in a decrease in CI, whereas stroke index and end diastolic volume did not change. Neither global ejection fraction (EF) nor end systolic volume changed significantly at any time, nor were there changes in the ECG or in regional ejection fractions (REF). The absence of changes in REF was consistent with lack of wall motion abnormalities of the left ventricle. Propofol alone and in combination with fentanyl does not alter LV performance in patients with good LV function.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262323

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  8 in total

1.  Arterial baroreflex attenuation during and after continuous propofol infusion.

Authors:  Y Kamijo; H Goto; K Nakazawa; K T Benson; K Arakawa
Journal:  Can J Anaesth       Date:  1992-11       Impact factor: 5.063

2.  Acute idiopathic heart failure following laparoscopic myotomy for achalasia of the esophagus.

Authors:  Kelly G Ural; Rodney J Landreneau; Grayson W Menard; Daniel Gomez
Journal:  Ochsner J       Date:  2015

Review 3.  Induction of anaesthesia: a guide to drug choice.

Authors:  Nathalie Nathan; Isabelle Odin
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  Anaesthesia for coronary artery surgery--a plea for a goal-directed approach.

Authors:  R I Hall
Journal:  Can J Anaesth       Date:  1993-12       Impact factor: 5.063

5.  Postoperative sedation with propofol infusion: haemodynamics and pharmacokinetics.

Authors:  C Sorbara; G Armellin; R Bonato; L Callegher; G Giron
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

6.  Intracoronary propofol does not decrease myocardial contractile function in the dog.

Authors:  S E Belo; R Kolesar; C D Mazer
Journal:  Can J Anaesth       Date:  1994-01       Impact factor: 5.063

7.  Cardiogenic shock following administration of propofol and fentanyl in a healthy woman: a case report.

Authors:  Alfredo Renilla González; Iñigo Lozano Martinez-Luengas; Sandra Secades González; Irene Alvarez Pichel; Paloma Alvarez Martinez; Elena Santamarta Liébana; Beatriz Díaz Molina
Journal:  J Med Case Rep       Date:  2011-08-16

8.  General anesthesia and positive pressure ventilation suppress left and right ventricular myocardial shortening in patients without myocardial disease - a strain echocardiography study.

Authors:  Keti Dalla; Odd Bech-Hanssen; Sven-Erik Ricksten
Journal:  Cardiovasc Ultrasound       Date:  2019-08-10       Impact factor: 2.062

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.